Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD3152 · 1 trial · 1 indication
Evaluation of the safety of IM or IV administration of AZD3152 will be done.
Evaluation of the safety of IM or IV administration of AZD3152 will be done.
Evaluation of the safety of IM or IV administration of AZD3152 will be done.
Pharmacokinetics (PK) characterization of AZD3152 in serum after a single IM or IV dose.
PK (Cmax) characterization of AZD3152 in serum after a single IM or IV dose.
PK (tmax) characterization of AZD3152 in serum after a single IM or IV dose.
PK (t1/2) characterization of AZD3152 in serum after a single IM or IV dose.
PK (AUClast) characterization of AZD3152 in serum after a single IM or IV dose.
PK (AUCinf) characterization of AZD3152 in serum after a single IM or IV dose.
PK (CL/F) characterization of AZD3152 in serum after a single IM.
PK (Vz/F) characterization of AZD3152 in serum after a single IM.
PK (CL) characterization of AZD3152 in serum after a single IV.
PK (Vz) characterization of AZD3152 in serum after a single IV.
PK (Vss) characterization of AZD3152 in serum after a single IV.
| Arm | Type | Description |
|---|---|---|
| AZD3152 Dose X (IM) | EXPERIMENTAL | Participants will receive dose X of AZD3152 on Day 1 as a single IM injection. |
| AZD3152 Dose X (IV) | EXPERIMENTAL | Participants will receive dose X of AZD3152 on Day 1 as an IV infusion. |
| AZD3152 Dose Y (IM) | EXPERIMENTAL | Participants will receive dose Y of AZD3152 on Day 1 as 2 sequential IM injections. |
| AZD3152 Dose Y (IV) | EXPERIMENTAL | Participants will receive dose Y of AZD3152 on Day 1 as an IV infusion. |
| AZD3152 Dose Z (IV) | EXPERIMENTAL | Participants will receive dose Z of AZD3152 on Day 1 as an IV infusion. |
| Pooled placebo | PLACEBO_COMPARATOR | Participant will receive placebo on Day 1 either via IM injection or IV infusion. |
| Name | Type | Description |
|---|---|---|
| AZD3152 | DRUG | AZD3152 will be administered via IM injection or IV infusion, as per the assigned arms. |
| Placebo | OTHER | Placebo is a matching volume of 0.9% sodium chloride, will be administered via IM injection or IV infusion, as per the assigned arms. |
Inclusion Criteria: * Healthy male or female participants. * Participants have suitable veins for cannulation or repeated venipuncture. * Negative SARS-CoV-2 RT-PCR or SARS-CoV-2 rapid antigen test result at Visit 1. * Body weight ≥ 45 kg and ≤ 110 kg and body mass index ≥ 18 and \<32 kg/m2 at Scre...
AZD3152 is an investigational small molecule being developed for COVID-19. It is intended for prophylaxis, meaning it is being studied to prevent COVID-19 infection. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
AZD3152 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy volunteers.
AZD3152 is in Phase 1 clinical development. A Phase 1 trial has been completed, which studied the drug's pharmacokinetics and exposure response when administered via intramuscular or intravenous routes. The drug remains investigational and has not received FDA approval.
AZD3152 has one completed clinical trial registered under NCT05872958. This Phase 1 study, titled "Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study," enrolled 98 healthy volunteers in the United States. The trial was randomized, double-blind, and placebo-controlled.
AZD3152 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A Phase 1 trial has been completed, but the drug has not yet progressed through the later stages of clinical testing required for regulatory approval.